HomeAI · summaries
Storia in 16 fonti
Merck gets US FDA nod for first-in-its-class oral cholesterol drug
The U.S. FDA has approved Merck's new cholesterol-lowering pill, Lipfendra. This oral medication works by blocking the PCSK9 protein, which helps lower bad cholesterol. Lipfendra offers an alternative for patients who dislike injectable treatments for heart disease. The drug is priced at $10.50 daily and will be available soon. Merck expects Lipfendra to significantly improve treatment for many high-risk patients.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Merck wins first approval of a PCSK9 cholesterol pill
The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former commissioner Marty Makary.
- ·
healio.com
FDA approves Lipfendra, the first oral PCSK9 inhibitor, to lower LDL
Merck and the FDA announced the approval of enlicitide 20 mg as an add-on to diet and exercise to lower LDL in adults with hypercholesterolemia and those with heterozygous…
